Clinical Trials Logo

Septic Shock clinical trials

View clinical trials related to Septic Shock.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT02706379 Active, not recruiting - Septic Shock Clinical Trials

Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain

Start date: June 2015
Phase: N/A
Study type: Interventional

Early goal directed therapy (EGDT) is an effective treatment for patients with septic shock, which is widely used in clinic. Fluid resuscitation can significantly reduce the mortality of patients with septic shock and improve the prognosis of patients with EGDT. However, in recent years, the standard of EGDT to determine the existence of the target of septic shock. Some studies have shown that there may be a manifestation of the deficiency of kidney and liver and other organs such as kidney, liver and other organs in the recovery of EGDT. Therefore, this experiment is to explore the brain perfusion and metabolism of the EGDT when the target is reached.The aim of this study was to investigate the effects of EGDT as a guide to the cerebral perfusion and metabolism in order to provide clinical evidence for the treatment of fluid resuscitation in patients with septic shock.

NCT ID: NCT02640846 Active, not recruiting - Septic Shock Clinical Trials

Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock

SCLM
Start date: December 2015
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate the effects milrinon and levosimandan on n heart function in septic cardiomyopathy and how norepinephrine affects the left and right ventricular function in patients with septick shock using pulmonary artery catheter, conventional and strain echocardiography.

NCT ID: NCT02120404 Active, not recruiting - Septic Shock Clinical Trials

Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock

THANE
Start date: April 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is : - to evaluate the hemodynamic tolerance of esmolol titrated to obtain a lowering of heart rate of 10% or 20%.

NCT ID: NCT01486524 Active, not recruiting - Septic Shock Clinical Trials

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

Start date: October 2011
Phase: N/A
Study type: Observational

The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death. This will be an international, multicenter, "prospective-retrospective", nonrandomized, controlled, outcome-blinded, genotype-blinded, matched-patients study. No prospective enrollment or treatment of patients will occur under this protocol. Retrospectively collected clinical data and DNA samples will be analyzed for existing cohorts of patients with severe sepsis who were previously treated with DrotAA (treatment group) or not (control group) as part of their standard care in an ICU.

NCT ID: NCT00510835 Active, not recruiting - Sepsis Clinical Trials

Protocolized Care for Early Septic Shock

ProCESS
Start date: March 2008
Phase: N/A
Study type: Interventional

The ProCESS study is large, 5-year, multicenter study of alternative resuscitation strategies for septic shock. The study hypothesizes that there are "golden hours" in the initial management of septic shock where prompt, rigorous, standardized care can improve clinical outcomes.